Nasdaq

FDA Grants SeaStar Medical Two New Breakthrough Device Designations for SCD Therapy to Treat Systemic Inflammatory Response in Adult and Pediatric Patients Undergoing Cardiac ...

DENVER, April 08, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients ...
Nasdaq

SeaStar Medical Receives FDA Approval for SCD-ADULT Study Funded by $3.6 Million NIH Grant

FDA approves SeaStar Medical's SCD-ADULT study for treating acute heart failure with renal issues, funded by a $3.6 million NIH grant. SeaStar Medical Holding Corporation announced that the U.S. FDA ...
Zacks Small Cap Research on MSN

ICU: Critical care innovation for AKI patients; initiating coverage of SeaStar Medical Holding Corp.

By David Bautz, PhD NASDAQ:ICU READ THE FULL ICU RESEARCH REPORT We are initiating coverage of SeaStar Medical Holding Corp. (NASDAQ:ICU) with a valuation of $12.00. SeaStar is a commercial-stage ...
Seeking Alpha

SeaStar Medical (Nasdaq: ICU) Announces Positive Interim Safety Findings from Ongoing Study Evaluating the Selective Cytopheretic Device (SCD) in Children

Interim study data show that SCD treatment is safe to use in pediatric patients with Acute Kidney Injury (AKI) requiring continuous kidney replacement therapy (CKRT) The SCD is currently being ...
KRQE Blogs

FDA Grants SeaStar Medical’s Selective Cytopheretic Device Breakthrough Device Designation for Hepatorenal Syndrome

DENVER, Oct. 18, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation ...